1. Rosenblum D., Joshi N., Tao W., Karp J.M.,  Peer D. (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications 9, 1-12. PDF
  2. Granot Y. and Peer D (2017) Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics- An innate immune system standpoint. Semin Immunol. PDF
  3. Rietwyk S., Peer D.(2017) Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 11, 7572−7586. PDF 
  4. Alvarez M.M., Aizenberg J., Analoui M., Andrews A.M., Bisker G., Boyden E.S , Kamm R.D., Karp j.M., Mooney D.J., Oklu R., Peer D., Stolzoff M.,  Strano M.S.,  Trujillo-de Santiago G., Webster T.J., Weiss P.S., Khademhosseini A. (2017) Emerging trends in Micro- and nanoscale technologies in medicine: from basic discoveries to translation. ACS Nano 11, 5195-5214. PDF
  5. Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, Peer D. (2017) Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.Molecular Therapy 25, 1491-1500. PDF
  6. Mizrahy S., Hazan-Halevy I., Landesman-Milo D. and  Peer D. (2017) Advanced strategies in immune modulation of cancer using lipid-based nanoparticles. Frontiers in Immunology 8, 69. PDF
  7. Anchordoquy T. J.,  Barenholz Y.,  Boraschi D., Chorny M.,  Decuzzi P., . Dobrovolskaia M.A, Farhangrazi Z. S.,  Farrell D., Gabizon A., Ghandehari H.,  Godin B.,  La-Beck N. M., Ljubimova J., Moghimi S.M., Pagliaro L.,  Park J.H.,  Peer D., Ruoslahti E., Serkova N.J., and Simber D. (2017) Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ASC Nano.  PDF
  8. Ng B.D. and Peer D. (2017) Orchestrating a symphony on a single conjugate: aptamer targeting, gene silencing, and immunomodulation to enhance antitumor response. Molecular Therapy 25, 5-7. PDF
  9. Hazan-Halevy I. , Landesman-Milo D., Rosenblum D. , Mizrahy S., Ng B.D., and Peer D. (2016) Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. Journal of Controlled Release, 244, 149-156. PDF
  10. Gutkin A., Cohen ZR, and Peer D. (2016) Harnessing nanomedicine for therapeutic intervention in glioblastoma. Expert Opinion on Drug Delivery ISSN: 1742-5247. PDF
  11. Ramishetti S, Landesman-Milo D, Peer D. (2016) Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. Journal of Drug Target 30, 1-6. PDF
  12. Singh M.S., Peer D. (2016) siRNA delivery:Current trends and future perspectives. Ther. Delivery 7(2), 52-53. PDF
  13. Singh M.S., Peer D. (2016) RNA nanomedicines: the next generation drugs? Current Opinion in Biotechnology 28-34PDF
  14. Landesman-Milo D, Peer D. (2016) Transforming nanomedicines from lab scale production to novel clinical modality. Bioconjug Chem. 27, 855-862. PDF
  15. Moyano DF., Liu Y., Peer D. and Rotello VM. (2016) Modulation of immune response using engineered nanoparticle surfaces. Small 12(1),76-82. PDF
  16. Moghimi SM., Hunter AC., Peer D. (2016) Platelet mimicry: The emperor's new clothes? Nanomedicine 12, 245-248. PDF
  17. Landesman-Milo D., Ramishetti S. and Peer D. (2015) Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer and Metastasis Reviews 34(2), 291-301. PDF
  18. Ganoth A, Cohen K.M, and Peer D (2015) Overcoming multidrug resistance with drug delivery strategies. Expert Opinion on Drug Delivery 12(2), 223-338. PDF
  19. Peer D. (2014) Precision medicine - delivering the goods? Cancer Letters 352, 2-3. PDF
  20. Goldsmith M., Abramovitz L., and Peer D (2014) Precision nanomedicine in neurodegenerative diseases. ACS Nano 8(3), 1958-1965. PDF
  21. Bogart L.K., Pourroy G., Murphy C,J., Puntes V.F., Pellegrino T., Rosenblum D., Peer D.*, and Lévy R* (2014) Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano 8(4), 3107–3122. *denotes equal contribution. PDF 
  22. Peer D (2014) Harnessing RNAi nanomedicine for precision therapy. Molecular and Cellular Therapies 2(5), 2-11. PDF
  23. Rosenblum D. and Peer D (2014) Omics-based nanomedicine: The future of personalized oncology. Cancer Letters. 352, 126-136. PDF
  24. Peer D, Giannechi N. and Luo D. (2013) Nanoparticles in biology. Journal of Materials Chemistry BPDF
  25. Mizrahy S., Landesman-Milo D., and Peer D (2013) Sweet fairytale: carbohydrates as backbones for glyconanomedicine. Israel Journal of Chemistry 53 (9-10), 616-629. PDF
  26. Howard KA. and Peer D. (2013) Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. Nanomedicine (Lond.) 8 (7), 1-3. PDF
  27. Peer D. (2013) A daunting task: manipulating leukocyte function with RNAi. Immunol Rev. 253, 185-197.PDF
  28. Vorup-Jensen T, Peer D. (2012) Nanotoxicity and the importance of being earnest. Adv. Drug Deliv. Rev. 64 (15) 1661-1662. PDF
  29. Daka A, Peer D. (2012) RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 64(13), 1508-1521. PDF
  30. Peer D. (2012) Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 64 (15), 1738–1748. PDF
  31. Barenholz Y, and Peer D (2012) Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chemistry & Physics of Lipids 165, 363-364. PDF
  32. Barenholz Y, Peer D. (2012) Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. Journal of Controlled Release 160(2), 115-116. PDF
  33. Landsman–Milo D, Peer D (2012) Altering the immune response with liposomes. Journal of Controlled Release 161, 600-608. PDF
  34. Mizrahy S, Peer D (2012). Polysaccharides as building blocks for nanotherapeutics. Chem. Soc. Rev. 41, 2623–2640. PDF
  35. Goldsmith M, Mizrahy S, Peer D (2011) Grand challenges in modulating the immune response with RNAi Nanomedicines. Nanomedicine 6(10), 1771-1785. PDF
  36. Peer D, Lieberman J. (2011) Special delivery: targeted therapy with small RNAs. Gene therapy 18(12), 1127-1133. PDF
  37. Elfakess R, Peer D. (2010) Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles. IDrugs 13(9), 626-631. PDF
  38. Weinstein S., and Peer D (2010) RNAi Nanomedicines: challenges and within opportunities the immune system. Nanotechnology 21(23), 232001, 1-13. PDF
  39. Peer D. (2010) Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. Journal of Controlled Release. 148(1), 63-68. PDF
  40. Kedmi R, and Peer D (2009) RNAi nanoparticles in the service of personalized medicine. Nanomedicine 4(8), 853-855. PDF
  41. Peer D, and Shimaoka M (2009) Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 8, 853-859. PDF
  42. Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2, 751-760. PDF
  43. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. (2007) Corneal gene therapy. Journal of Controlled Release 124(3), 107-133. PDF
  44. Peer D, and Margalit R (2006) Fluoxetine and reversal of multidrug resistance. Cancer Letters 237,180-187. PDF